Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deciphera Pharmaceuticals Inc.

www.deciphera.com

Latest From Deciphera Pharmaceuticals Inc.

Deciphera's Ripretinib Cuts GIST Death Risk By 64%; US Filing On Track For Early 2020

Overall survival for patients with gastrointestinal stromal tumors (GIST) in the fourth-line setting was 15.1 months versus 6.6 months for placebo, building on impressive progression-free survival results.

Clinical Trials Business Strategies

Finance Watch: Five More Biopharmas Enter US Queue Even As IPO Returns Dip

Public Company Edition: SpringWorks has the biggest IPO ambitions of recent US filers. Also, Deciphera raises $400m after good data and Protalix seeks strategic alternatives.

Financing Strategy

Deciphera Plans Ripretinib NDA Filing For Q1 2020 On Phase III GIST Data

CEO Steve Hoerter sees best-in-class potential for the drug based on both efficacy and safety in the fourth-line gastrointestinal stromal tumor setting, with the INVICTUS trial having positive readthrough to the ongoing Phase III INTRIGUE study in second-line GIST.

Clinical Trials Cancer

Asia Deal Watch: BeiGene And Celgene Exit Their Anti-PD-1 Collaboration

The Chinese firm regains all rights to tislelizumab ahead of the closing of Celgene’s merger with Bristol-Myers Squibb. BeiGene also forms cancer JV with US biotech SpringWorks.

Deals Asia Pacific
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Deciphera Pharmaceuticals LLC
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Deciphera Pharmaceuticals Inc.
  • Senior Management
  • Steve Hoerter, Pres. & CEO
    Tucker Kelly, EVP, CFO
    Daniel Flynn, PhD, EVP, CSO
    Christopher J Morl, CBO
    Stephen Ruddy, CTO
    Matthew L Sherman, MD, EVP, CMO
  • Contact Info
  • Deciphera Pharmaceuticals Inc.
    Phone: (781) 209-6400
    500 Totten Pond Rd.
    6th Fl.
    Waltham, MA 02451
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register